SCYX

+ Watchlist + Portfolio

SCYNEXIS, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.15
52-Week Range: $3.53 – $10.48
Market Cap: $51.94M
P/E (TTM): —
EPS (TTM): -0.92
Dividend Yield: —

Advanced Metrics

Price/Book: 0.78
PEG Ratio: —
Return on Equity: -18.38%
Return on Assets: -20.82%
Gross Margin: 100.00%
Operating Margin: -3308.51%
Profit Margin: -53.26%
Current Ratio: 9.65
Debt/Equity: 0.03
Total Debt: $1.95M
Free Cash Flow: $-7.32M
Revenue Growth: -82.80%
Earnings Growth: —
Enterprise Value: $-201.04K

SCYX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$5.09M	$140.14M	$3.75M	$20.60M
Cost of Revenue	$628.00K	$15.62M	$0.00	—
Gross Profit	$4.46M	$124.52M	$3.75M	—
Research & Development	$27.26M	$30.93M	$26.41M	$22.28M
Selling, General & Admin	$62.96M	$20.92M	$14.46M	$14.39M
Operating Expenses	$90.22M	$51.85M	$40.86M	$36.67M
Operating Income	-$85.76M	$72.67M	-$37.12M	-$16.07M
EBITDA	-$61.70M	$70.89M	-$20.31M	-$8.44M
Pretax Income	-$67.51M	$67.18M	-$21.14M	-$8.61M
Income Tax	-$4.70M	$138.00K	$151.00K	$0.00
Net Income	-$62.81M	$67.04M	-$21.29M	-$8.61M
Diluted EPS	-11.76	11.12	-3.52	-1.36
Diluted Shares	5.33M	6.05M	6.06M	6.24M

SCYX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$45.81M	$34.05M	$16.05M	$21.26M
Receivables	$2.10M	$21.83M	$10.26M	$0.00
Inventory	$899.00K	$0.00	—	—
Current Assets	$79.06M	$102.12M	$72.18M	$40.37M
Total Assets	$87.81M	$128.41M	$90.64M	$59.03M
Current Liabilities	$17.62M	$16.30M	$24.10M	$5.73M
Long-Term Debt	$45.39M	$12.16M	—	—
Total Debt	$48.60M	$15.08M	$16.27M	$2.17M
Total Liabilities	$84.58M	$55.45M	$35.57M	$9.65M
Retained Earnings	-$422.29M	-$355.25M	-$376.54M	-$385.14M
Shareholders' Equity	$3.23M	$72.96M	$55.08M	$49.38M
Working Capital	$61.44M	$85.81M	$48.08M	$34.64M

SCYX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$79.88M	$60.16M	-$24.01M	-$5.28M
Capital Expenditure	-$9.00K	—	—	—
Free Cash Flow	-$79.89M	$60.16M	-$24.01M	-$5.28M
Depreciation & Amortisation	$606.00K	$580.00K	$0.00	—
Stock-Based Compensation	$3.69M	$2.62M	$3.35M	$2.85M
Investing Cash Flow	-$27.39M	-$34.88M	$6.15M	$24.31M
Financing Cash Flow	$48.60M	-$36.72M	-$139.00K	-$14.17M
Net Change in Cash	-$58.67M	-$11.44M	-$18.00M	$4.85M

SCYX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$257.00K	$1.36M	$334.00K	$18.65M	$0.00
Research & Development	$5.14M	$7.14M	$5.45M	$4.54M	$12.35M
Selling, General & Admin	$3.73M	$3.78M	$3.29M	$3.58M	$4.59M
Operating Expenses	$8.87M	$10.93M	$8.74M	$8.13M	$16.94M
Operating Income	-$8.61M	-$9.56M	-$8.40M	$10.52M	-$16.94M
EBITDA	-$5.22M	-$6.88M	-$8.59M	$12.26M	-$21.30M
Pretax Income	-$5.39M	-$6.88M	-$8.59M	$12.26M	-$21.30M
Income Tax	$0.00	$0.00	$0.00	$0.00	—
Net Income	-$5.39M	-$6.88M	-$8.59M	$12.26M	-$21.30M
Diluted EPS	-0.88	-1.12	-1.36	—	-3.36
Diluted Shares	6.18M	6.22M	6.24M	—	6.37M

SCYX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$6.94M	$11.02M	$14.80M	$21.26M	$36.67M
Receivables	$9.72M	$10.00M	$10.00M	$0.00	—
Current Assets	$52.22M	$56.50M	$48.69M	$40.37M	$62.69M
Total Assets	$67.92M	$60.69M	$51.07M	$59.03M	$77.63M
Current Liabilities	$8.96M	$10.86M	$8.47M	$5.73M	$15.90M
Total Debt	$2.49M	$2.39M	$2.28M	$2.17M	$2.06M
Total Liabilities	$17.38M	$16.23M	$14.64M	$9.65M	$36.32M
Retained Earnings	-$381.93M	-$388.81M	-$397.40M	-$385.14M	-$406.44M
Shareholders' Equity	$50.53M	$44.47M	$36.43M	$49.38M	$41.31M
Working Capital	$43.26M	$45.63M	$40.23M	$34.64M	$46.79M

SCYX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.46M	-$7.50M	-$8.72M	$18.40M	-$8.10M
Free Cash Flow	-$7.46M	-$7.50M	-$8.72M	$18.40M	-$8.10M
Stock-Based Compensation	$819.00K	$820.00K	$526.00K	$687.00K	$580.00K
Investing Cash Flow	$12.44M	$11.27M	$12.42M	-$11.82M	-$525.00K
Financing Cash Flow	-$14.08M	$0.00	$29.00K	-$115.00K	$24.04M
Net Change in Cash	-$9.11M	$3.78M	$3.72M	$6.46M	$15.41M

Market Snapshot

About

SCYNEXIS, Inc. is a biotechnology company focused on developing novel anti-infectives to address unmet medical needs. The company lead product candidate targets invasive fungal infections in immunocompromised patients who have limited or no treatment options.